To determine the importance of the thrombin substrate recognition exosite for fibrinogen binding in the formation of both arterial and venous thrombi, we evaluated the antithrombotic effects of the tyrosine-sulfated dodecapeptide from residues 53-64 of hirudin (H peptide) in a nonhuman primate model. This peptide was studied because it inhibits thrombin cleavages of fibrinogen by simple competition without blocking enzyme catalytic-site function. When an exteriorized arteriovenous access shunt model was used in baboons (Papio anubis), thrombus formation was induced by placing a thrombogenic device made of (i) a segment of tubing coated covalently with type I collagen, which generated platelet-rich thrombi under arterial flow conditions, and (i) two subsequent annular regions of flow expansion that produced fibrin-rich thrombi typically associated with venous valves and veins.
to the device for 40 min interrupted, in a dose-response fashion, formation of fibrin-rich thrombus in the regions of disturbed flow and generation of fibrinopeptide A. In contrast, H peptide did not inhibit the capacity of platelets to deposit on the collagen surface (P > 0.2 at all doses) or to form hemostatic plugs (as assessed by measurements of bleeding time; P > 0.1 at all doses). These findings suggest that, by competitive inhibition of fibrinogen binding to thrombin, fibrin-rich venous-type thrombus formation may be selectively prevented. This strategy may be therapeutically attractive for preserving normal platelet function when conventional anticoagulant therapy is contraindicated.
Inhibition of the activity or production of thrombin constitutes an important global antithrombotic strategy because thrombin is centrally involved in the formation of both arterial and venous thrombosis (1, 2) . Although arterial thrombosis generally involves platelet deposition at sites of vessel injury, high shear flow conditions, and secondary activation of the coagulation cascade (1), venous thrombosis usually involves local fibrin production in regions of stasis and disturbed blood flow with minimal vascular injury (3) . Thrombin amplifies the thrombotic process by activation of platelets and through positive feedback activation of two plasma cofactors, coagulation factor V and factor VIII. In addition, thrombin stabilizes and enlarges the thrombotic mass by cleavage of fibrinogen to form fibrin, with release of activation peptides A and B, and by activation of factor XIII (1) . Thus, inhibitors of thrombin activity or thrombin generation have been found to exhibit potent antithrombotic effects in animal models of both arterial (4) (5) (6) and venous (7) thrombosis.
The most potent natural inhibitor of thrombin is hirudin, a 65-amino acid protein from the salivary glands of the medicinal leech (8) . Hirudin inhibits thrombin by forming a tight stoichiometric complex (8) (9) (10) . Recombinant forms of hirudin (11-13) have potent antithrombin activities and are under evaluation as clinical agents (5) (6) (7) 14) . Structure-function studies of hirudin, documenting the importance of the inhibitor's carboxyl-terminal segment in the formation of a hirudin-thrombin complex, have led to the design and characterization of synthetic, tyrosine-sulfated hirudin peptides (9, 10, 15, 16) . The synthetic, tyrosine-sulfated dodecapeptide comprising residues 53-64 of hirudin (H peptide or hirugen) is a competitive inhibitor of thrombin-catalyzed hydrolysis of fibrinogen but has no effect on thrombin amidolytic activities (17) . Thus, H peptide appears to be a specific antagonist of a fibrinogen-binding substrate recognition site in thrombin. In addition, H peptide inhibits thrombin in tests of platelet aggregation, thromboxane A2 generation, and platelet densegranule release in vitro (18) . In the present study, we have evaluated the antithrombotic effects of H peptide in baboons. A model of complex thrombus formation was used to separately determine the effects of H peptide on platelets vs. coagulation-related mechanisms (19) . The baboon was chosen for these studies because of its hemostatic and immunologic similarities to man (20) .
ANIMAL STUDIES
Dose-response and control studies were done in each of five normal male juvenile baboons Papio anubis (9-11 kg). Platelet counts averaged 375 ± 13 x 103 platelets per 1l, hematocrits were 32 ± 1%, and fibrinogen levels were 3.1 ± 0.2 g/liter, as determined using reported methods (19, 20) ; these values were equivalent for the different study groups. All animals had chronic exteriorized silicone rubber arteriovenous access shunts surgically placed between the femoral artery and vein (4, 21) . These shunts did not shorten platelet survival or .produce measurable activation of platelets or coagulation factors (21, 22) .
In each experiment a thrombogenic device was incorporated into the shunt system as an extension segment and exposed to nonanticoagulated flowing blood for 40 min (19 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. pump (Cole-Parmer) positioned distally to the device; the wall shear rate in the collagen tubing was calculated to be 100 sec-1. This device generated two types of thrombus in unanticoagulated flowing blood: a proximal collagen segment ofplatelet-rich thrombus, simulating arterial thrombosis, and a distal chamber of fibrin-rich thrombus also rich in erythrocytes, as seen in venous thrombosis (19) .
Autologous baboon blood platelets were labeled with 1 mCi of 111indium-oxine (1 Ci = 37 GBq), according to described methods (4, 19) . The average labeling efficiency of this method was >90%. After allowing at least 1 hr for the reinfused cells to distribute within the vasculature, the thrombogenic device was incorporated into the shunt system for 40 min. The accumulation of 111In-lableled platelets within each region of the device was measured in real time using a y scintillation camera (model 4/11; Picker, Northford, CT). Data were analyzed by using a computer-assisted image processing system (Medical Data Systems A3; Medtronic, Ann Arbor, MI) interfaced with the camera. Images were acquired at 5-min intervals. The total number of deposited platelets (labeled plus unlabeled cells) was calculated by dividing the deposited platelet activity (cpm) by the whole blood platelet 11'In activity (cpm/ml) and multiplying by the circulating platelet count (platelets/ml) as measured in each experiment. Radioactivity values reflected platelet activity only; all blood measurements were corrected for the small fraction of non-platelet isotope in each experiment. The plasma (nonplatelet) activity per ml of whole blood was calculated for each experiment by multiplying the activity per ml of plasma by the factor (1 -hematocrit; i.e., the proportion of blood consisting of plasma). Plasma activities averaged 9 ± 1% of whole blood activities in these studies. Homologous baboon fibrinogen was purified and labeled with 125I as described (19) . The labeled fibrinogen preparation was >90%6 clottable by thrombin in vitro. Ten minutes before initiating thrombus formation, 5 ,Ci of 125I-labeled fibrinogen was injected i.v. After blood exposure for 40 min, the device was removed, thoroughly rinsed with isotonic saline, and then cut into regions corresponding to the collagen segment and expanded chambers. After allowing at least 30 days for 1"'In to decay (half-life, 2.8 days) the device components were counted for 15I-labeled fibrinogen radioactivity with a y counter. Total fibrin accumulation (labeled plus unlabeled) was calculated by dividing deposited fibrinogen/fibrin activity (cpm) by clottable fibrinogen 125I activity (cpm/ml) and multiplying the plasma fibrinogen concentration (mg/ml) as measured in each experiment.
Bleeding times were performed on the shaved volar forearm of the baboon by using the standard template method (4, 19) . All procedures were approved by the Institutional Animal Care and Use Committee in accordance with 1986 federal guidelines.
H Peptide. H peptide (hirugen) was prepared by solid-phase peptide synthesis, chemical derivatization of Tyr-11 to yield (OS03) Tyr-11, and purification by reverse-phase HPLC to >95% purity (15) . In vitro, H peptide prolonged the thrombin clotting time (TCT) in a dose-dependent manner. The final concentration of H peptide that doubled TCT (with bovine thrombin) in baboon plasma averaged 13 ,ug/ml. By using identical conditions, the amount of recombinant hirudin (Ciba-Geigy) that doubled TCT was 0.6 ,ug/ml-that is, a 25-fold lower concentration in molar specific activities. H peptide was diluted in saline before use and was infused proximal to the device throughout the 40 min of study. Because the controlled blood flow rate through the device (20 ml/min) was low relative to the animal blood volume (700 ml), higher local concentrations of peptide were achieved than would have been required for systemic i.v. infusion by using one-eighth of the peptide ( at three different doses, 0.5, 15, and 75 mg/kg total doses, administered continuously over 40 min. Effects of peptide on coagulation were determined on blood collected both immediately distal to the thrombogenic device and systemically (Table 1) . Both the APTT and the TCT were prolonged in a dose-response manner. After 10 min of peptide administration at the highest concentration (75 mg/kg per 40 min), the APTT was prolonged 4-fold over baseline values (126 ± 3 sec vs. 31 ± 3 sec), and the TCT was >30) sec (Table 1) in blood collected distal to the thrombus-forming device. At all doses, plasma concentrations of H peptide were constant throughout the 40-min experiment ( Table 1 ). The systemic plasma concentrations of H peptide were reduced with a corresponding lesser effect on coagulation times, as compared with values achieved locally within the device (Table 1) . Thus, after 10-min infusion at the highest dose, the systemic plasma concentration of H peptide was about one-eighth (180 ± 6 ,ug/ml) of that in the device (1452 + 394 ,gg/ml). This plasma concentration of H peptide (180 ,ug/ml) was not associated with any prolongation of bleeding time (P > 0. 1; Table 1 1 and 2. In control studies (saline infusion alone) the collagen segment and the low-shear chamber regions accumulated comparable numbers of platelets (17.9 ± 1.5 x 108 vs. 16.6 + 2.5 x 108; P > 0.5). However, the chambers accumulated 5 to 6 times more 125I-labeled fibrin than the collagen segment (3.39 ± 0.57 mg vs. 0.62 ± 0.12 mg, respectively; P < 10-5).
H peptide interrupted thrombus formation in the low-shear regions of disturbed flow in a dose-dependent manner (Fig.  1) . The smallest infused dose (0.5 mg/kg per 40 min) reduced fibrin deposition in the chambers by 50%o (1.69 ± 0.22 mg vs. 3.30 ± 0.57 mg; P = 0.03); at the highest dose, fibrin accumulation was decreased by =80%o (0.81 ± 0.35 mg; P = 0.006) (Fig. 1B) . At the high dose, platelet deposition in the chambers was also largely abolished (2.56 ± 0.39 x 108 platelets vs. 16.59 ± 2.51 x 108 platelets in controls; P = 0.001) (Fig. LA) .
However, in the range of doses tested, H peptide did not reduce either the platelet or fibrin components of thrombi on the collagen segment (Fig. 2) . For example, at the highest dose (75 mg/kg per 40 min), the deposition of 1"'In-labeled platelets and 125I-labeled fibrin on the collagen segment was equivalent to control values (P > 0.2 in both cases).
Markers of platelet activation (plasma levels of plateletspecific granular proteins (3-TG and PF4) and the thrombin cleavage product of fibrinogen (plasma FPA) were assayed on the blood-collected effluent from the thrombogenic device (Fig. 3) . In control studies (saline infusion) the levels of these markers increased 10-to 15-fold after device insertion. The elevation in FPA levels was prevented by H peptide infusion in a dose-dependent manner-i.e., infusion of H peptide at 75 mg/kg per 40 min reduced the levels of FPA from 48.7 ± 8.2 to 12.7 ± 2.0; P = 0.009. H peptide was less effective in reducing platelet granular release; PF4, but not 3-TG, was detectably reduced only at the highest infused dose (3TG, 25.9 ± 2.6 ng/ml vs. 35.4 ± 9.1 ng/ml, P = 0.37; PF4, 27.0 ± 2.1 vs. 42.4 ± 4.9 ng/ml, P = 0.03). DISCUSSION X-ray crystallographic analysis of the hirudin-thrombin complex (24) and, more recently, the H peptide-thrombin complex (J.M.M. and A. Tulinsky, unpublished data) provide molecular detail for the inhibition of thrombin by hirudin and hirudin fragments. The NH2-terminal 48 residues of hirudin are found to maintain a globular fold and participate in the inhibition of the enzyme catalytic site. Direct interaction of the a-NH2 of residue 1 in hirudin is observed with the serine and, possibly, histidine of the catalytic triad. These and other interactions permit inhibition by hirudin of thrombin amidolytic activity. In the structures of the hirudin-thrombin and H peptide-thrombin complexes, the carboxyl-terminal tail of residues =50-65 occupy a defined substrate-binding groove and an anion-binding or substrate-recognition exosite. These interactions are discrete and spatially separated (by at least 20 A) (25) (15, 17) .
Because H peptide selectively inhibits the substrate binding of thrombin, H peptide provides a useful probe for discriminating between binding-dependent and catalyticdependent activities in thrombus formation. Thus, we have compared the relative antithrombotic activities of this dodecapeptide on platelet-dependent and fibrinogen-dependent thrombosis by using a thrombogenic device designed to simulate both arterial and venous flow conditions (19, 23 fibrin-rich thrombus formation in low-shear regions of venous-type flow but fails to affect platelet-dependent thrombotic processes characteristic of hemostatic plug formation and arterial-type thrombus formation. In contrast, hirudin is a potent inhibitor of both arterial (5, 6) and venous (7, 14) thrombus formation in vivo. In our studies H peptide inhibited thrombin cleavage of fibrinogen (as measured by plasma FPA levels) and reduced the formation of fibrin-rich thrombus in a dose-dependent manner. The smallest dose, 0.5 mg/kg per 40 min, produced a detectable prolongation of ex vivo coagulation times and decreased fibrin deposition in the regions ofdisturbed flow by 50%o; at the highest dose, venous-type thrombus accumulation in the chamber region was largely abolished. The activity levels of H peptide required to inhibit venous-type thrombosis were consistent with those obtained with recombinant hirudin (14) , as determined by using clotting assays for specific activity in vitro (15) . Thus, inhibition of the substrate recognition site of thrombin is alone sufficient for interruption of fibrinogen-dependent thrombosis. In contrast to its activities in preventing fibrin-dependent thrombus formation, H peptide exhibited no significant effects toward platelet accumulation on a collagen surface. This finding is concordant with observations that the formation of plateletdependent thrombus requires active-site inhibition of thrombin as produced by agents such as D-Phe-Pro-Arg-CH2CI (4) and hirudin (5, 6) . Taken together, these studies indicate that this thrombotic process is mediated by the catalytic activity of thrombin and not by exosite binding of thrombin to platelets.
Importantly, the highest dose of H peptide administered was found to prolong APTT and TCT measurements to values comparable to those produced by hirudin at doses that clearly inhibit high-shear platelet-dependent thrombus formation and prolonged bleeding times (6) . The fact that H peptide only weakly inhibits factor V activation by thrombin (26) could, in part, explain the present findings with H peptide because the development of platelet-rich thrombi may depend strongly on secondary activation of the coagulation cascade. However, the observation that H peptide failed to prolong bleeding times at doses that affected the clotting time tests, suggests that, in contrast to hirudin (6, 14) , H peptide maintains a wider margin of safety by not affecting hemostatic plug formation. Consequently, H peptide may be useful for treatment of venous thrombotic disorders where heparin administration is contraindicated-e.g., in patients deficient in antithrombin III, with heparin-induced thrombocytopenia, or in association with surgical procedures.
